Lipoprotein-associated phospholipase A2: A new therapeutic target

被引：4

作者：

Lonn, Eva ^{[1
]}

机构：

[1] McMaster Univ, Hamilton Hlth Sci & Populat Hlth Res Inst, Hamilton, ON, Canada

来源：

CANADIAN JOURNAL OF CARDIOLOGY | 2010年 / 26卷

关键词：

Atherosclerosis; Inflammation; Lipoprotein-associated phospholipase A(2); Plaque rupture; CORONARY-ARTERY-DISEASE; ACTIVATING-FACTOR-ACETYLHYDROLASE; C-REACTIVE PROTEIN; MIDDLE-AGED MEN; FUTURE CARDIOVASCULAR EVENTS; LOW-DENSITY-LIPOPROTEIN; HEART-DISEASE; ISCHEMIC-STROKE; RISK-FACTORS; ENDOTHELIAL DYSFUNCTION;

D O I：

10.1016/S0828-282X(10)71058-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Lipoprotein-associated phospholipase A(2) is in enzyme produced by inflammatory cells, which binds to apolipoprotein B-containing lipoproteins and degrades oxidatively modified phospholipids in low-density lipoprotein cholesterol pail-iciest leading to formation of proinflammatory and cytotoxic products. Experimental studies suggest a role for lipoprotein-associated phospholipase A(2) in the formation of advanced rupture-prone artherosclerotic lesions, and epidemiological investigations have linked it to increased cardiovascular risk. Ongoing trials are evaluating the role of novel pharmacological inhibitors of this enzyme, such its darapladib, in the management or high-risk coronary artery disease patients.

引用

页码：27A / 31A

页数：5

共 50 条

[41] Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis
Wang, Yuan
Liu, Gang
Song, Haiqing
Cao, Catherine
Ji, Xunming
Cao, Guodong
FRONTIERS IN NEUROLOGY, 2022, 13
[42] Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes
Canning, Paul
Kenny, Bridget-Ann
Prise, Vivien
Glenn, Josephine
Sarker, Mosharraf H.
Hudson, Natalie
Brandt, Martin
Lopez, Francisco J.
Gale, David
Luthert, Philip J.
Adamson, Peter
Turowski, Patric
Stitt, Alan W.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (26) : 7213 - 7218
[43] Lipoprotein-associated phospholipase A2 levels are elevated in obese children
Sakka, S.
Kaminioti, C.
Pervanidou, P.
Lazopoulou, N.
Kanaka-Gantenbein, C.
Chrousos, G.
Papassotiriou, I.
CLINICAL BIOCHEMISTRY, 2011, 44 (07) : 539 - 539
[44] Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular diseases
Siekmeier, Ruediger
Grammer, Tanja B.
Scharnagl, Hubert
Stojakovic, Tatjana
Koenig, Wolfgang
Maerz, Winfried
LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2010, 34 (04): : 217 - 222
[45] Racial variation in lipoprotein-associated phospholipase A2 in older adults
Lee, Keane K.
Fortmann, Stephen P.
Varady, Ann
Fair, Joan M.
Go, Alan S.
Quertermous, Thomas
Hlatky, Mark A.
Iribarren, Carlos
BMC CARDIOVASCULAR DISORDERS, 2011, 11
[46] Risk of stroke and elevated levels of lipoprotein-associated phospholipase A2
Alberts, Mark J.
Ballantyne, Christie
Elkind, Mitchell S.
STROKE, 2008, 39 (02) : 642 - 642
[47] The Emerging Role of Lipoprotein-associated Phospholipase A2 in Cerebrovascular Disease
Kakkos, S. K.
Tsolakis, I. A.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2012, 43 (02) : 160 - 160
[48] Lipoprotein-Associated Phospholipase A2 Activity and Risk of Recurrent Stroke
Elkind, Mitchell S. V.
Tai, Wanling
Coates, Kristen
Paik, Myunghee C.
Sacco, Ralph L.
CEREBROVASCULAR DISEASES, 2009, 27 (01) : 42 - 50
[49] Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2
Saougos, Vasilios G.
Tambaki, Afroditi P.
Kalogirou, Mihalis
Kostapanos, Michael
Gazi, Irene F.
Wolfert, Robert L.
Elisaf, Moses
Tselepis, Alexandros D.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (10) : 2236 - 2243
[50] Lipoprotein associated phospholipase A2 as a target of therapy
Macphee, CH
Nelson, JJ
Zalewski, A
CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (04) : 442 - 446

← 1 2 3 4 5 →